Patrick Huynh, DO
Internal Medicine · Norcross, GANPI 1245761303
Payments from drug & device makers
Across 272 payments — averaging $63.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$13K
- Novo Nordisk$1K
- Amgen$498
- GSK$327
- AbbVie$276
- Pfizer$176
- plus $2K from 34 others
What the payments were for
- Speaking & faculty fees$11,05064%
- Travel & lodging$7104%
- Food & beverage$5,53032%
- Entertainment$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 58 | $13,230 |
| Novo Nordisk | 61 | $1,010 |
| Amgen(2 entities) | 26 | $498 |
| GSK | 12 | $327 |
| AbbVie | 15 | $276 |
| Pfizer | 10 | $176 |
| Lilly USA, LLC | 11 | $175 |
| Abbott | 9 | $164 |
| Dexcom, Inc. | 3 | $142 |
| Amarin Pharma, Inc. | 8 | $126 |
| Bayer | 6 | $109 |
| E.r. Squibb & Sons, L.L.C. | 1 | $106 |
| Boehringer Ingelheim | 6 | $104 |
| Merck | 5 | $76 |
| Otsuka America Pharmaceutical, Inc. | 3 | $69 |
| Gilead | 3 | $68 |
| Astellas Pharma US Inc | 2 | $64 |
| Exact Sciences | 3 | $62 |
| Agios Pharmaceuticals, Inc. | 3 | $59 |
| Lucid Diagnostics Inc. | 2 | $44 |
| Eisai Inc. | 3 | $39 |
| Sanofi-aventis U.S. LLC | 2 | $38 |
| Upsher-smith Laboratories LLC | 2 | $34 |
| Inspire Medical Systems, Inc. | 2 | $33 |
| Boston Scientific | 1 | $30 |
| Edwards Lifesciences | 1 | $27 |
| Echosens North America, Inc. | 1 | $20 |
| Neurocrine Biosciences, Inc. | 1 | $20 |
| Arbor Pharmaceuticals, Inc. | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Medtronic | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Philips North America LLC | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Corcept Therapeutics | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Optos, Inc. | 1 | $14 |
| Theracosbio, LLC | 1 | $13 |
| Phathom Pharmaceuticals, Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,304 in reported general payments places this provider in the 95th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 116 | $90,981 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 88 | $67,204 |
| ProliaDenosumab | 39 | $65,391 |
| JardianceEmpagliflozin | 76 | $56,758 |
| VemlidyTenofovir Alafenamide | 21 | $27,924 |
| XareltoRivaroxaban | 30 | $24,106 |
| OzempicSemaglutide | 22 | $22,030 |
| EliquisApixaban | 29 | $19,441 |
| JanuviaSitagliptin Phosphate | 20 | $18,421 |
| MounjaroTirzepatide | 13 | $13,977 |
| TradjentaLinagliptin | 19 | $13,713 |
| LinzessLinaclotide | 18 | $12,846 |
| Aimovig AutoinjectorErenumab-Aooe | 12 | $8,191 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 13 | $8,112 |
| Amlodipine-ValsartanAmlodipine Besylate/Valsartan | 62 | $4,484 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $13,230 | $90,981116 claims |
| Boehringer IngelheimJardiance, Tradjenta | $104 | $70,47195 claims |
| GSKTrelegy Ellipta | $327 | $67,20488 claims |
| AmgenProlia | $498 | $65,39139 claims |
| GileadVemlidy | $68 | $27,92421 claims |
| Novo NordiskOzempic | $1,010 | $22,03022 claims |
| PfizerEliquis | $176 | $19,44129 claims |
| MerckJanuvia | $76 | $18,42120 claims |
| Lilly USA, LLCMounjaro | $175 | $13,97713 claims |
| AbbVieLinzess | $276 | $12,84618 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Norcross
- Paul BradleySavannah$76.4M
- Kimball JohnsonAtlanta$51.1M
- Bram WieskopfWoodstock$21.9M
- Dwight BlakeUnion City$13.3M
- Charlotte Grayson-MathisFayetteville$9.6M
- Christopher RecknorGainesville$9.2M
- James HarperJohns Creek$9.2M
- Robert Springer IiiAtlanta$5.3M
- Thomas MoriaritySavannah$4.6M
- Charles KempAlbany$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.